Trevena (NASDAQ:TRVN) Earns Sell Rating from Analysts at StockNews.com

StockNews.com started coverage on shares of Trevena (NASDAQ:TRVN) in a research note issued to investors on Thursday. The firm issued a sell rating on the biopharmaceutical company’s stock.

Trevena Stock Performance

Shares of NASDAQ:TRVN opened at $1.25 on Thursday. The firm has a fifty day moving average of $1.60 and a 200 day moving average of $2.07. Trevena has a 52-week low of $1.13 and a 52-week high of $11.50. The firm has a market capitalization of $1.08 million, a PE ratio of -0.03 and a beta of 1.05.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.